Post-earnings recap
Reported
Thu, Apr 25, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that BioMarin Pharmaceutical is facing challenges, particularly reflected in the EPS miss. The stock's slight decline of 0.21% suggests that investors may have anticipated a tougher quarter. Without specific guidance, uncertainty remains about the company's near-term performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.32 | N/A | -785.65% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced in the quarter. They emphasized a commitment to their long-term goals without offering specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on its long-term strategies despite the current EPS miss.